Business Wire

ARTHUR-D.-LITTLE

17.12.2021 15:13:12 CET | Business Wire | Press release

Share
Arthur D. Little Publishes Special 135th Anniversary Edition of PRISM Magazine

Arthur D. Little (ADL) has published Who Says It Can’t Be Done? – the latest edition of its innovation magazine PRISM. As well as celebrating the company’s 135-year history, this special edition looks ahead to both the future of business and the consulting industry itself.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211217005298/en/

The magazine features five key articles:

  • Rebalancing For Tomorrow – The ability to help clients anticipate the future, embrace new opportunities, and transform their operations has always been a central part of ADL’s consulting philosophy. This article looks at the challenges that business faces today, identifies important priorities for the future, and reflects on how companies can get ready to meet them.
  • Why Consultancy Matters: A Historical Perspective – What is the exact nature of management consultancy’s value? Does consulting merely provide a similar service to that of the accountancy or legal professions, or does it provide a different type of value? This article explores how management consultancy has helped to shape the world we live in today as illustrated by the history of ADL.
  • The Future Of Consultancy – In today’s volatile environment, companies are looking for more than just me-too solutions to remain competitive. The consulting industry needs to reconfigure its approach and reject obsolete legacy models if it is to stay relevant to modern business. This article looks at some of the ways in which consulting must change in order to create real value for its clients.
  • Inventors, Innovators, Pathfinders – Since the days of Arthur Dehon Little himself, ADL has been driven by hugely talented individuals, all pathfinders in their own right. This article celebrates some of the extraordinary people who have both led ADL and pioneered its unique approach to consultancy, inventing new solutions and breaking down barriers along the way.
  • Who Says It Can’t Be Done? – It was only after a management buyout (MBO) on 30 December 2011 that ADL was truly reborn as a successful partnership with a rapidly expanding business. In this interview with Ignacio Garcia-Alves, who led the MBO and has been ADL’s Chief Executive Officer ever since, he shares his insights on how the company was transformed and the lessons learned over the past ten years.

Ignacio García Alves, Global Chairman and Chief Executive Officer of Arthur D. Little , comments: “PRISM always offers the best in thought-leading insight and commentary on the key topics of the day, and this edition is no exception – but with ADL hitting the milestone of 135 years of constant innovation, we couldn’t resist also looking back on what’s made it such a unique and pioneering company.”

This latest edition of PRISM can be viewed here: https://tinyurl.com/9hyefpch

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye